imatinib mesylate has been researched along with Cramp in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| den Hollander, D; Desar, IME; Dirkson, AR; Gelderblom, H; Husson, O; Kraaij, W; Oosten, A; Reyners, AKL; Steeghs, N; van der Graaf, WTA; van Oortmerssen, G; Verberne, S | 1 |
| Beck, M; Chae, H; Kang, YK; Ma, J; Ryu, MH | 1 |
| Alimena, G; Baccarani, M; Baratè, C; Bergamaschi, M; Breccia, M; Cottone, F; Dabusti, M; Deliliers, GL; Di Lorenzo, R; Efficace, F; Fava, C; Leoni, P; Levato, L; Luciano, L; Mandelli, F; Martino, B; Rambaldi, A; Rosti, G; Sica, S; Simula, MP; Specchia, G; Stagno, F; Turri, D; Veneri, D; Vignetti, M | 1 |
| Bhargava, S; Kumar, M; Malhotra, B; Malhotra, H; Rathore, OS; Sharma, P | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Arrigoni, E; Baratè, C; Ceccherini, F; Cervetti, G; Ciabatti, E; Cornolti, F; D'Avolio, A; Danesi, R; Di Paolo, A; Domingo, D; Fava, C; Fontanelli, G; Galeotti, L; Galimberti, S; Grassi, S; Guerrini, F; Laurino, M; Petrini, M; Polillo, M; Saglio, G | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Frustaci, AM; Latagliata, R; Santopietro, M; Stefanizzi, C | 1 |
| Druker, B; Gathmann, I; Guilhot, F; Larson, RA; O'Brien, SG; So, C; Waltzman, R | 1 |
| Baccarani, M; Breccia, M; Caocci, G; Cardoni, A; Chie, W; Cocks, K; Efficace, F; Kossak-Roth, U; Mandelli, F; Naeem, A; Nicolatou-Galitis, O; Saussele, S; Sprangers, M; Vignetti, M | 1 |
| Deininger, MW; Druker, BJ; Ford, JM; O'Brien, SG | 1 |
| Guilhot, F | 1 |
| Lipton, JH; Medeiros, BC | 1 |
2 review(s) available for imatinib mesylate and Cramp
| Article | Year |
|---|---|
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Topics: Antineoplastic Agents; Arthralgia; Benzamides; Bone Marrow; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Edema; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Cell Growth Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Muscle Cramp; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vomiting | 2003 |
Indications for imatinib mesylate therapy and clinical management.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Eruptions; Edema; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Piperazines; Pyrimidines | 2004 |
3 trial(s) available for imatinib mesylate and Cramp
| Article | Year |
|---|---|
Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Treatment Outcome; Young Adult | 2020 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Diarrhea; Drug Administration Schedule; Edema; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
7 other study(ies) available for imatinib mesylate and Cramp
| Article | Year |
|---|---|
Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.
Topics: Cross-Sectional Studies; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires | 2022 |
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Fatigue Syndrome, Chronic; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Muscle Cramp; Musculoskeletal Pain; Piperazines; Pyrimidines; Quality of Life; Social Behavior; Young Adult | 2013 |
Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Diarrhea; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Nausea; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2014 |
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Edema; Factor Analysis, Statistical; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Octamer Transcription Factor-1; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Sex Characteristics | 2017 |
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.
Topics: Benzamides; Exanthema; Hemorrhage; Humans; Imatinib Mesylate; Incidence; Leukemia, Myeloid, Chronic-Phase; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Weight Gain | 2008 |
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Benzamides; Edema; Europe; Fatigue; Female; Health Personnel; Humans; Imatinib Mesylate; Iraq; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Muscle Cramp; Patients; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Social Support; Surveys and Questionnaires; Taiwan; Young Adult | 2012 |
Chlordiazepoxide for imatinib-induced muscular cramps.
Topics: Antineoplastic Agents; Benzamides; Chlordiazepoxide; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; GABA Modulators; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Muscle Cramp; Piperazines; Pyrimidines | 2006 |